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Abstract
Background: Deregulation of the Wnt/ β-catenin signal transduction pathway has been implicated in the
pathogenesis of tumours in the mammary gland, colon and other tissues. Mutations in components of this
pathway result in β-catenin stabilization and accumulation, and the aberrant modulation of β-catenin/TCF
target genes. Such alterations in the cellular transcriptional profile are believed to underlie the
pathogenesis of these cancers. We have sought to identify novel target genes of this pathway in mouse
mammary epithelial cells.
Methods: Gene expression microarray analysis of mouse mammary epithelial cells inducibly expressing a
constitutively active mutant of β-catenin was used to identify target genes of this pathway.
Results: The differential expression in response to ∆Nβ-catenin for five putative target genes, Autotaxin,
Extracellular Matrix Protein 1 (Ecm1), CD14, Hypoxia-inducible gene 2 (Hig2) and Receptor Activity
Modifying Protein 3 (RAMP3), was independently validated by northern blotting. Each of these genes
encodes either a receptor or a secreted protein, modulation of which may underlie the interactions
between Wnt/β-catenin tumour cells and between the tumour and its microenvironment. One of these
genes, Hig2, previously shown to be induced by both hypoxia and glucose deprivation in human cervical
carcinoma cells, was strongly repressed upon ∆Nβ-catenin induction. The predicted N-terminus of Hig2
contains a putative signal peptide suggesting it might be secreted. Consistent with this, a Hig2-EGFP fusion
protein was able to enter the secretory pathway and was detected in conditioned medium. Mutation of
critical residues in the putative signal sequence abolished its secretion. The expression of human HIG2 was
examined in a panel of human tumours and was found to be significantly downregulated in kidney tumours
compared to normal adjacent tissue.
Conclusions:  HIG2 represents a novel non-cell autonomous target of the Wnt pathway which is
potentially involved in human cancer.
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Background
The Wnt/β-catenin signal transduction pathway plays a
central role in metazoan development, controlling such
diverse processes as cell growth, proliferation and organo-
genesis [1]. Wnt-1 is the prototypic member of this large
family of secreted glycoproteins and was originally identi-
fied as a gene insertionally activated by mouse mammary
tumour virus [2]. Wnt-1 is one of a number of Wnt family
members which act to control the cellular level of β-cat-
enin. Wnt proteins bind seven-pass transmembrane
receptors of the Frizzled family, and a signal is transduced
via Dishevelled to a complex which contains the Adeno-
matous Polyposis Coli (APC), Axin and Glycogen Syn-
thase Kinase-3β (GSK-3β) proteins [3,4]. This signal
antagonizes the phosphorylation of β-catenin by GSK-3β.
There are four phosphorylation sites in the N-terminus of
β-catenin which, in the absence of Wnt signal, are phos-
phorylated by Casein Kinase I alpha and GSK-3β [5,6].
This phosphorylation leads to the ubiquitination and sub-
sequent proteasomal degradation of β-catenin [7]. Inhibi-
tion of β-catenin phosphorylation by Wnt signalling leads
to the accumulation of β-catenin which forms a bipartite
complex with members of the TCF/LEF transcription fac-
tor family and activates the transcription of target genes, a
process which is regulated by multiple interacting factors
[8].
Overexpression of Wnt-1 in the mammary glands of trans-
genic mice leads to extensive hyperplasia and tumorigen-
esis [9]. APC was identified as the tumour suppressor gene
mutated in the hereditary colorectal cancer syndrome,
Familial Adenomatous Polyposis [10,11]. Mutations in
Axin and β-catenin have also been detected in tumours of
the colon and other tissues [12]. Deregulation of this
pathway appears to be play a contributory role in a signif-
icant proportion of human tumours of epithelial origin
and hence, the identification of effector genes of this path-
way is an important step towards the elucidation of the
mechanisms involved.
Many of the Wnt targets thus far identified are cell-cycle
regulators [13,14] and transcription factors [15-20], and
function in a cell-autonomous manner, providing insight
into the mechanisms by which tumour cells deregulate
proliferation and inhibit apoptosis. Tumours are complex
organs composed of tumour cells, stromal fibroblasts,
endothelial cells and cells of the immune system; and
reciprocal interactions between these cell types in the
tumour microenvironment are necessary for tumour
growth [21,22]. Here we postulate that proteins secreted
by Wnt/β-catenin tumour cells and receptors expressed by
these cells may play roles in mediating interactions
between neighbouring tumour cells or between tumour
cells and their microenvironment. Consequently, in this
study we have focussed our attention on identifying novel
genes encoding receptors and secreted proteins.
Methods
Cell culture
All reagents were purchased from Sigma unless otherwise
noted. HC11 mouse mammary epithelial cells were cul-
tured in 5% CO2 at 37°C in RPMI 1640, supplemented
with 10% Foetal Bovine Serum, 2 mM L-glutamine, 2.5
µg/ml insulin, 5 ng/ml epidermal growth factor and 50
µg/ml gentamycin [23]. HC11-lacZ and HC11-∆Nβ-cat-
enin cells were routinely cultured in 2 µg/ml tetracycline
to repress transcription of the tetracycline-regulated trans-
gene. HEK293 and MDCK cells were grown in DMEM
supplemented with 10% Foetal Bovine Serum.
The HC11-lacZ  and HC11-∆Nβ-catenin  cell lines were
generated by infecting the cells with an ecotropic retrovi-
rus (TRE-tTA) in which the tTA cDNA is under the control
of a tetracycline responsive promoter. Consequently, tTA
expression is minimal in the presence of tetracycline and,
upon tetracycline withdrawal, tTA activates its own tran-
scription in an autoregulatory manner [24]. HC11 cells
expressing tTA were subsequently infected with ecotropic
retroviruses derived from RevTRE (Clontech) which
directed the expression of either β-galactosidase or ∆Nβ-
catenin in a tetracycline dependent manner.
Bosc23 cells were used to produce ecotropic retroviruses
[25]. Cells were transiently transfected with the appropri-
ate retroviral construct and the supernatant was collected
48 hours post-transfection. Polybrene was added to a final
concentration of 5 µg/ml and the supernatant was added
to HC11 cells for 24 hours. HC11 cells were then sub-
jected to antibiotic selection using either 250 µg/ml G418
or 200 µg/ml hygromycin B as appropriate.
RNA isolation
Cell monolayers were washed twice in ice-cold Phosphate
Buffered Saline and lysed by addition of Trizol (Invitro-
gen). Total RNA was isolated according to the manufac-
turer's instructions. PolyA+ RNA was purified from total
RNA using Oligotex (Qiagen) according to the manufac-
turer's instructions.
Northern blotting
10 µg of total RNA from each cell line was fractionated on
a denaturing formaldehyde agarose gel and transferred to
a positively charged nylon membrane (Hybond N+,
Amersham Pharmacia Biotech) in 10x SSC. Membranes
were prehybridised for four hours in 50% (v/v) forma-
mide, 5X SSPE, 2X Denhardt's reagent, 0.1% (w/v) SDS
and 100 µg/ml denatured herring sperm DNA. Radiola-
belled probes were prepared from PCR-amplified cDNA
clones using the Rediprime II kit (Amersham PharmaciaBMC Cancer 2005, 5:3 http://www.biomedcentral.com/1471-2407/5/3
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Biotech) according to the manufacturer's instructions. EST
sequences corresponding to the coding sequence of the
genes-of-interest were identified by BLAST [26] and
obtained from the I.M.A.G.E. consortium through the UK
Human Genome Mapping Project Resource Centre (Hinx-
ton, UK). ESTs bearing the following I.M.A.G.E. cloneIDs
were used: Autotaxin – 533819; CD14 – 2936787; Ecm1
717050;  Hig2  – 367488; Ramp3  – 615797, HIG2
4366895). Following overnight hybridisation with the
labelled probe, the membranes were washed twice in 1X
SSC, 0.1% (w/v) SDS at room temperature for 20 mins,
and twice in 0.2X SSC, 0.1% (w/v) SDS at 68°C for 10
mins and exposed to film at -80°C for 48 hours. Bound
probe was quantitated using a phosphorimager (Molecu-
lar Dynamics).
Western blotting
Cell monolayers were rinsed twice with ice-cold Phos-
phate Buffered Saline and total cell lysates were prepared
by scraping cells into a minimal volume of 50 mM Tris.
HCl pH 7.5, 150 mM NaCl, 0.5% NP40 and Complete
protease inhibitor cocktail (Roche). Aliquots containing
80 µg protein from each sample were analysed by SDS-
PAGE [27], and transferred electrophoretically to a PVDF
membrane. Mouse monoclonal antibodies were used to
detect tTA (Clontech), β-catenin (Transduction Laborato-
ries) and EGFP (Santa Cruz Biotechnology). Samples of
conditioned medium were concentrated 12-fold using
Microcon YM-10 centrifugal filter units (Millipore) prior
to analysis.
Construction of plasmids
A BgIII fragment containing the lacZ cDNA was excised
from the CMV-lacZ construct (a gift of Trevor Dale) and
sub-cloned into BamHI digested RevTRE to make RevTRE-
lacZ. A plasmid containing a myc-tagged ∆Nβ-catenin was
obtained from Hans Clevers. The myc-tagged ∆Nβ-catenin
was excised with KpnI and NotI and the ends were
blunted, and subcloned into HpaI digested RevTRE to
make RevTRE-∆Nβ-catenin. The mouse Hig2 open reading
frame was amplified by PCR from I.M.A.G.E. cDNA clone
367488 using the primers TTTACTAGTAGGAGCT-
GGGCACCGTCGCC and TTTTACCGGTGCCTGCACTC-
CTCGGGATGGATGG. The PCR product was digested
with AgeI and SpeI and subcloned into the AgeI and NheI
sites in pEGFP-C1 (Clontech) to make the Hig2-EGFP
fusion gene. Site directed mutagenesis was carried out by
the method of Sawano and Miyawaki (2000) [28]. The
primer TGCTGAACCTCGAGGAGCTGGGCATCATG was
used to make the Hig2-EGFP(Y8V9/D8D9) mutant.
Transient transfections
Transient transfections were performed using Lipo-
fectamine (Invitrogen) according to the manufacturer's
instructions. Briefly, 1.5 × 105 cells were plated in 3.5 cm
wells on the day prior to transfection. Each well was trans-
fected with a total of 0.9 µg DNA under serum-free condi-
tions for six hours, after which the cells were washed and
incubated for a further 48 hours before assaying
expression.
β-galactosidase activity assay
For the tetracycline dose response curve, 5000 HC11-lacZ
cells for each condition, were cultured in triplicate in 96
well plates for 72 hours, and beta-galactosidase activity
was determined as previously described [24].
Results
Generation of HC11-lacZ and HC11-∆Nβ-catenin cell 
lines
Stable cell lines were generated in which either ∆Nβ-cat-
enin or β-galactosidase was expressed in a tetracycline
dependent manner. These cell lines were established using
a novel autoregulatory system in which the expression
level of the tetracycline transactivator (tTA) protein is
minimised during routine culture and is induced upon
withdrawal of tetracycline with concomitant upregulation
of the transgene-of-interest [24]. This strategy helps to
minimise deleterious effects due to tTA toxicity.
A dose-response analysis for the HC11-lacZ cell line is
shown in Figure 1A. β-galactosidase expression is effec-
tively repressed at tetracycline concentrations in excess of
20 ng/ml and is strongly induced in the absence of tetra-
cycline. The N-terminal truncation mutant of β-catenin
can be detected by western blotting by both its myc-
epitope tag and an anti-β-catenin antibody (Figure 1B).
tTA expression is detectable only in the absence of tetracy-
cline demonstrating the autoregulatory nature of this
system.
Microarray analysis
Transgene expression was induced in HC11-lacZ  and
HC11-∆Nβ-catenin cells by withdrawal of tetracycline for
72 hours. Total RNA was isolated, from which mRNA was
purified. cDNAs were labelled and hybridized to an 8962
element Incyte mouse GEM1 cDNA microarray (Incyte
Genomics, Palo Alto, CA). These data are provided as sup-
plementary material (See Additional file 1). Among those
genes upregulated were two genes shown by other work-
ers to be transcriptional targets of this pathway – Fibronec-
tin [29] and Autotaxin [30] (data not shown) – suggesting
that our model of Wnt/β-catenin signalling deregulation
results in the activation of a set of target genes which over-
laps, at least partially, with pathway targets in other cell
lines. The microarray experiment described here was per-
formed only once but differential expression was repeat-
edly validated by northern blotting from independent
samples for the genes discussed here.BMC Cancer 2005, 5:3 http://www.biomedcentral.com/1471-2407/5/3
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Validation of targets
Five genes were selected for further study – Extracellular
Matrix Protein 1 (Ecm1), Autotaxin, Receptor Activity Modify-
ing Protein 3 (Ramp3), Cd14 and Hypoxia Inducible Gene 2
(Hig2). Each putative target gene was initially subjected to
a secondary screen by Northern blotting to confirm the
differential expression in response to ∆Nβ-catenin (Figure
2). RNA samples used for Northern blotting were from
independent induction experiments to those used for
microarray analysis, thus demonstrating repeatedly by
two distinct methods that the transcript levels of these
genes are altered in cells overexpressing ∆Nβ-catenin. The
expression level of each of the transcripts was quantitated
using a phosphorimager and normalised to the expression
of Gapdh mRNA in the samples. The data in Figure 2 rep-
resent film exposure times ranging between 24 and 72
hours. Quantitations were performed using short (one
hour or less) exposures to a phosphorimager screen, such
that the signal intensity was not saturating.
Molecular cloning of mouse Hig2
Hypoxia Inducible Gene 2 encodes a 63 amino acid
polypeptide and was one of several genes identified in a
screen for genes regulated by hypoxia in a human cervical
epithelial cell line [31]. HIG2 shares no sequence similar-
ity with other known proteins. In order to facilitate the
functional analysis of this gene, ESTs were identified
which encoded mouse and rat Hig2, and the sequences of
chimpanzee and baboon were inferred from genomic
sequence data. A multiple alignment of the inferred
amino acid sequences shows that these polypeptides are
highly similar (Fig 3A). Analysis of these sequences using
a Kyte-Doolittle hydrophobicity plot showed that the N-
termini of these proteins contain a series of hydrophobic
amino acids (Fig 3B). This region of hydrophobicity was
reminiscent of a signal peptide and sequence analysis
using the signal peptide prediction program, SignalP
[32,33] supported this possibility.
Hig2 has an N-terminal signal peptide and is secreted
To investigate the subcellular localisation of Hig2, a Hig2-
EGFP fusion gene was constructed and expressed in both
HC11 and Madin-Darby Canine Kidney (MDCK) cells by
transient transfection (Figure 4a and 4c). In both cell
lines, Hig2-EGFP is localised to large round vesicle-like
structures in the cytoplasm. Similar observations were
made in HEK-293 cells (data not shown). The fluores-
cence was detected predominantly around the periphery
of these structures suggesting that they do not consist of
solid masses of aggregated protein. When two aspartate
residues were introduced to the putative signal peptide by
site-directed mutagenesis, Hig2(Y8V9/D8D9)EGFP, this
distinctive subcellular localization was abolished (Fig 4B
and 4D). These large structures did not colocalize with
either markers of mitochondria (pDsRed2-mito, Clon-
tech), nor lipid droplets (Nile Red, Molecular Probes) nor
with markers of endosomes or lysosomes (pulse-chase
analysis with TRITC-dextran); data not shown. However,
in live HC11 cells transfected with Hig2-EGFP, observa-
tions at high magnification revealed that the cytoplasm of
Generation of stable HC11 cell lines expressing β-galactosi- dase and ∆Nβ-catenin in a tetracycline dependent manner Figure 1
Generation of stable HC11 cell lines expressing β-galactosi-
dase and ∆ Nβ-catenin in a tetracycline dependent manner. 
(a) HC11-lacZ cells – β-galactosidase activity of cell lysates 
following incubation for three days at the indicated tetracy-
cline concentrations. β-galactosidase expression is effectively 
repressed at 20 ng/ml tetracycline. The assay was carried out 
in triplicate and results are presented as the mean β-galactos-
idase activity (normalised to the protein concentration of the 
samples) ± standard error. (b) Western blot of total cell 
lysates from HC11-∆Nβ-catenin cells cultured ± tetracycline. 
The N-terminal deletion mutant of β-catenin is detected by 
both its myc-epitope tag and the anti-β-catenin antibody. tTA 
was detected only in the absence of tetracycline, confirming 
the autoregulatory nature of the induction system.
Confirmation of differential expression of putative target  genes in response to ∆Nβ-catenin overexpression Figure 2
Confirmation of differential expression of putative target 
genes in response to ∆Nβ-catenin overexpression. The 
expression level of each gene in the HC11-lacZ (L) and 
HC11-∆Nβ-catenin (∆N) cell lines was assessed by Northern 
blotting. The fold-induction was quantitated using a phos-
phorimager under non-saturating conditions, normalised to 
the expression of GAPDH mRNA in the samples and is 
expressed as fold change relative to the expression level of 
that gene in the HC11-lacZ cell line.BMC Cancer 2005, 5:3 http://www.biomedcentral.com/1471-2407/5/3
Page 5 of 9
(page number not for citation purposes)
these cells contained many very small solid green vesicles
moving along the cytoskeleton. These vesicles were
approx 1/100 the size of the large vesicles shown in Fig 4A
and 4C, and were not observed in cells transfected with
either Hig2(Y8V9/D8D9)EGFP or EGFP alone. The rapid-
ity of this motion in live cells, even at room temperature,
precluded capture of these images but suggested the pos-
sibility that measurable amounts of secreted Hig2-EGFP
might be found in the culture medium. HEK-293 cells
were chosen as they could be transfected at high efficiency
(approx 80%), the presence of the green transport vesicles
was confirmed, and 48 hours after transfection samples of
total cell lysate and conditioned medium were analysed
by western blotting. Secreted Hig2-EGFP was detected in
the conditioned medium of Hig2-EGFP cells, but not
Hig2(Y8V9/D8D9)EGFP cells (Fig 5). Multiple bands
were detected in cell lysates for both Hig2-EGFP fusion
proteins: whether these represent artifactual degradation
products or physiologically relevant biological entities is
as yet unknown. Such multiple banding has also been
observed with other EGFP-fusion proteins targeted to the
secretory pathway (Amphiregulin-EGFP, PK unpublished
observations). At least one of the bands may result from
internal translation initiation at the consensus Kozak ini-
tiation sequence of pEGFP-C1 which is located between
the Hig2 and EGFP open reading frames.
EGFP was also detected in the conditioned medium. This
is consistent with previous reports of GFP secretion via a
non-classical Brefeldin A-insensitive pathway [34]. In this
study, several cell lines are described (including HEK293)
in which wild-type GFP is released from the cell without
passing through the golgi apparatus. Thus, it is formally
possible that, instead of its secretion being directed by the
putative signal peptide, HIG2-EGFP might be released
from the cell via this pathway in a manner specifically
dependent on the EGFP moiety. The presence of post-
translational modifications acquired during endoplasmic
reticulum/golgi apparatus mediated secretion would
exclude the latter hypothesis. The altered mobility of HIG-
2-EGFP in the medium suggested that it might be glyco-
sylated, however the mobility was not changed by treat-
ment with the glycosidase PNGaseF, suggesting that this
Sequence analysis of five mammalian Hig-2 proteins Figure 3
Sequence analysis of five mammalian Hig-2 proteins. (a) Mul-
tiple sequence alignment of Hig2 amino acid sequences of 
mouse, rat, human, chimpanzee and olive baboon shows that 
these proteins share strong sequence similarity. (b) A repre-
sentative Kyte-Doolittle hydrophobicity plot using the mouse 
Hig2 amino acid sequence indicates these proteins have 
hydrophobic N-termini, reminiscent of a signal peptide. Subcellular localisation of a Hig2-EGFP fusion protein and  mutational analysis of the putative signal peptide in HC11 and  MDCK cells Figure 4
Subcellular localisation of a Hig2-EGFP fusion protein and 
mutational analysis of the putative signal peptide in HC11 and 
MDCK cells. (a and c) Hig2-EGFP is localised to large spher-
ical vesicles located in the cytoplasm. (b and d) The intro-
duction of two aspartate residues into the putative 
hydrophobic signal peptide abolishes the vesicular subcellular 
localisation of the mutant protein.BMC Cancer 2005, 5:3 http://www.biomedcentral.com/1471-2407/5/3
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secreted protein is not glycosylated (data not shown). Pre-
vious studies using GFP fused to a signal peptide directing
entry into the ER demonstrated that, in this redox
environment, the cysteine residues of GFP form
intermolecular disulphide bridges which result in
oligomerization of GFP molecules [35]. Oligomers of
Hig2-EGFP were detected (Fig 5, black arrowheads) but
no oligomerization of EGFP was observed. Hig2 itself
does not contain cysteine residues, thus the oligomeriza-
tion is mediated by the EGFP domains. These data are
consistent with HIG2-EGFP entry into the classical secre-
tory pathway. Collectively, these data demonstrate that
Hig2 contains a functional N-terminal signal peptide and
is likely a secreted protein.
Expression of HIG2 in human tumours
To investigate the relevance of HIG2 in human tumours,
the expression level of this gene was examined in 68
tumour cDNA samples compared to normal adjacent tis-
sue from the same patients using a Matched Tumour/Nor-
mal cDNA blot (Clontech) (Figure 6A). The levels of HIG2
were approximately similar in most of the tumour types
examined but were strongly and consistently downregu-
lated in most of the cases of kidney and stomach tumours
analysed. These data suggest that the downregulation of
HIG2 observed upon deregulated β-catenin signalling in
vitro may be of clinical relevance in human tumours.
Discussion
cDNA microarray analysis of the transcriptional changes
resulting from overexpression of a constitutively active β-
catenin revealed a panel of putative target genes of the
Wnt/β-catenin pathway in mouse mammary epithelial
cells. This differential expression was confirmed by North-
ern blotting in five cases.
Autotaxin was originally identified as a secreted enzyme
with potent motility stimulating activity [36] and has
Hig2-EGFP fusion protein is secreted from transfected cells Figure 5
Hig2-EGFP fusion protein is secreted from transfected cells. 
Western blot analysis of total cell lysates and conditioned 
medium from (1) untransfected HEK293 cells and cells trans-
fected with plasmids encoding (2) EGFP, (3) Hig2-EGFP, (4) 
Hig2(Y8V9/D8D9)EGFP. Oligomers of HIG2-EGFP formed 
by intermolecular disulphide bridges are indicated by 
arrowheads.
(a) Analysis of HIG2 mRNA expression on a human cDNA  array containing matched tumour and normal samples from  68 patients Figure 6
(a) Analysis of HIG2 mRNA expression on a human cDNA 
array containing matched tumour and normal samples from 
68 patients. For each pair, the tumour sample is on top. The 
bottom row of the array contains cDNA from cell lines (left 
to right: HeLa, Daudi, K562, HL-60, G361, A549, MOLT-4, 
SW480 and Raji). (b) Quantitative analysis by phosphorim-
ager. Vertical dashed lines indicate ± 2-fold difference. HIG2 
expression is broadly similar in most pairs, but is strongly and 
consistently downregulated in most of the kidney and stom-
ach tumours analysed.BMC Cancer 2005, 5:3 http://www.biomedcentral.com/1471-2407/5/3
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both pyrophosphatase and phosphodiesterase activity
[37]. Transplantation experiments in athymic mice
showed that ras-transformed NIH-3T3 fibroblasts became
significantly more tumorigenic, invasive and metastatic
when transfected with Autotaxin [38], and purified recom-
binant Autotaxin has potent angiogenic activity in vivo
[39]. Autotaxin has been shown to be regulated by both
Wnt-1 and retinoic acid [30]. Autotaxin has been shown
to have lysophospholipase activity and the effects of Auto-
taxin on tumour cell motility are mediated by its
conversion of lysophosphatidylcholine to lysophospha-
tidic acid (LPA), a potent signalling molecule [40,41].
Extracellular Matrix Protein 1 was first identified as a
novel 85 KDa protein secreted by a mouse osteogenic
stromal cell line [42]. In situ hybridisation showed that
Ecm1 was strongly expressed in most newly formed blood
vessels and experiments using purified recombinant Ecm1
showed that it could increase the proliferation rate of vas-
cular endothelial cells in vitro and also stimulate angio-
genesis in vivo. The ability to induce de novo angiogenesis
is an absolute requirement for tumours to grow beyond a
size which can be readily perfused by oxygen and nutri-
ents from the interstitial fluid. ECM1 is overexpressed in
many epithelial tumours including 73% of breast
tumours analyzed [43]. Homozygous loss-of-function
mutations in the human ECM1 gene were recently identi-
fied by linkage analysis as the causative mutations behind
Lipoid Proteinosis, a rare autosomal recessive disorder
characterized by hyaline deposition in the skin, mucosae
and viscera [44]. The identification of Autotaxin and Ecm1
as genes upregulated by activation of this pathway,
together with VEGF [45] suggests that deregulation of
Wnt/β-catenin signalling during tumour initiation and
progression may be one of the factors which promotes
tumour angiogenesis.
CD14, which can function as both a receptor and a
secreted protein, was downregulated upon ∆Nβ-catenin
expression. CD14 is a glycosyl-phosphatidylinositol-
linked cell surface protein, preferentially expressed in
monocytes, where it acts as a receptor for Lipopolysaccha-
ride Binding Protein:Lipopolysaccharide complexes [46].
Soluble CD14 (sCD14) is also expressed in mammary epi-
thelial cells in vitro and has been detected in human milk
where it is postulated to play a role in neonatal immunity
[47], and is strongly upregulated in mammary luminal
epithelial cells in vivo at the onset of involution [48].
Receptor Activity Modifying Protein 3 (RAMP3) was down-
regulated upon ∆Nβ-catenin induction and is one of three
members of the RAMP family. These proteins are involved
in mediating the cellular response to the neuropeptides
calcitonin, calcitonin gene related peptide, amylin and
adrenomedullin. The RAMP family members function as
chaperones for the seven transmembrane domain G-pro-
tein coupled receptors for these neuropeptides, shuttling
the receptor to the cell surface and altering receptor
glycosylation. The ligand binding phenotype of the
receptor is dependent on the RAMP family member with
which it is associated [49]. RAMP3-Calcitonin Receptor
(CR) heterodimers form a functional receptor for amylin
[50], and RAMP3-Calcitonin-Receptor-Like-Receptor
(CRLR) heterodimers act as an adrenomedullin receptor
[51].
Expression of both CR and CRLR was detected in HC11 by
RT-PCR (data not shown) suggesting that functional
receptor-RAMP complexes are present in this cell line.
Adrenomedullin, the ligand for the CRLR/RAMP3 recep-
tor dimer, functions as a growth factor in several human
tumour cell lines [52], in addition to promoting angio-
genesis in vivo [53] via CRLR/RAMP3 and CRLR/RAMP2
receptor dimers [54,55].
Hypoxia-inducible gene 2 (Hig2) was one of several genes
identified in a representational difference analysis screen
for genes regulated by hypoxia in a human cervical epithe-
lial cell line. The human gene encodes a 63 amino acid
polypeptide of unknown function [31]. Expression of
mouse  Hig2  was downregulated in HC11 cells overex-
pressing  ∆Nβ-catenin. The identification of a group of
mammalian orthologues revealed a well conserved hydro-
phobic region in the N-terminus, reminiscent of a signal
peptide. A Hig2-EGFP fusion protein entered the secretory
pathway and was detected in conditioned medium of
transfected cells. The introduction of a pair of charged
amino acids into the hydrophobic region abolished secre-
tion, lending support to the hypothesis that this region
contains a functional signal peptide. The nature of the
large vesicular structures observed in Hig2-EGFP overex-
pressing cells is as yet unclear. Mammary epithelial cells
are known to contain membrane-enclosed lipid droplets,
as well as a variety of vesicular compartments involved in
the secretion of casein, citrate, lactose and calcium [56],
however the presence of these vesicles in MDCK and
HEK293 cells argues that they are not mammary specific.
Indeed, co-localization experiments suggest that these
structures are neither mitochondria, lysosomes, endo-
somes nor lipid droplets. Given the demonstration that
Hig2 is secreted, these structure most likely correspond to
overexpressed Hig2-EGFP in transit through the endoplas-
mic reticulum and golgi apparatus. As no antibody is
available against Hig2, it was not possible to investigate
the localisation of the endogenous protein, but these data
represent a useful initial step in the functional characteri-
sation of this gene.
Analysis of the expression of HIG2  using a matched
Tumour/Normal tissue cDNA array showed that HIG2 isBMC Cancer 2005, 5:3 http://www.biomedcentral.com/1471-2407/5/3
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widely expressed. In most cases, the levels of HIG2 in the
tumours and the associated normal tissue controls were
similar.  HIG2  was, however, strongly and consistently
downregulated in the majority of the kidney and stomach
tumours analysed. This represents an significant valida-
tion of our in vitro findings in human tumours, and sug-
gests that HIG2 may exert a tumour suppressive effect in
vivo. Human HIG2 is located on 7q32.2, a commonly
deleted region in several tumour types, most prominently
leukaemias and lymphomas [57]. Deletion analysis of 7q
in a panel of patients with Splenic Lymphoma with
Villous Lymphocytes by Catovsky and colleagues suggests
that a critical tumour suppressor is located on 7q32 [58].
Conclusions
The identification of this panel of candidate target genes
for this clinically important signal transduction pathway
adds to those identified by other workers in a variety of
model systems and suggests that, as well as promoting
tumour cell proliferation and survival in a cell
autonomous manner, this activation of this pathway is
likely to have a series of non-cell autonomous effects.
Here we have focussed on the identification of Wnt/β-cat-
enin target genes that are either secreted signalling mole-
cules or receptors. It is likely that such targets are involved
in mediating autocrine proliferation, promotion of angio-
genesis and the mediation of reciprocal communication
between Wnt/β-catenin tumours and their microenviron-
mental milieu.
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